Table 3. Multivariate analysis for the association between clinical characteristics with survival in advanced pancreatic cancer patients.
| HR | 95%CI | P value | |
|---|---|---|---|
| Gender | |||
| Male | 1 | ||
| Female | 0.680 | 0.443-1.043 | 0.177 |
| Age | |||
| ≤57 | 1 | ||
| >57 | 1.099 | 0.982-1.016 | 0.914 |
| KPS | |||
| 90 | 1 | ||
| 70-80 | 1.174 | 1.037-1.419 | 0.049 |
| Pathological differention | |||
| Well-moderate | 1 | ||
| Poor | 1.159 | 1.078-1.417 | 0.037 |
| Disease extension | |||
| Distant metastasis | 1 | ||
| Locally advanced | 0.761 | 0.467-1.012 | 0.087 |
| First-line chemotherapeutic regimens | |||
| Gemcitabine monotherapy | 1 | ||
| Gemcitabine and S-1/capecitabine | 0.966 | 0.548-1.812 | 0.990 |
| Gemcitabine and platinum drugs | 0.929 | 0.363-2.374 | 0.878 |
| Gemcitabine and nab-paclitaxel | 0.846 | 0.520-1.376 | 0.501 |
| Second-line chemotherapy | |||
| No | 1 | ||
| Yes | 0.681 | 0.476-0.972 | 0.035 |
| Timing of CIN | |||
| Non-early | 1 | ||
| Early | 0.696 | 0.466-0.938 | 0.027 |
Hazard ratios of survival and 95% CI were estimated with Cox’s proportional hazards model.
Adjusted for: Gender, Age, KPS, Pathology differention, Disease extension, First-line chemotherapy regimens, Second-line chemotherapy, Timing of CIN